Bindu Kanapuru MD
Myeloproliferative Disorder Hematology-Oncology
Physician
Join to View Full Profile
3300 Gallows RdFalls Church, VA 22042
Are you Dr. Kanapuru?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bindu Kanapuru, MD is a hematologist in Falls Church, Virginia. She is currently licensed to practice medicine in Virginia and Maryland.
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 2008 - 2011
MedStar Health Georgetown University/Harbor HospitalResidency, Internal Medicine, 2004 - 2007
Madras Medical CollegeClass of 1996
Andhra Medical College NTRClass of 1996
Certifications & Licensure
VA State Medical License 2011 - 2026
MD State Medical License 2010 - 2012
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsModernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters.Lauren Merz, Monique Hartley-Brown, Maureen Achebe, Craig Cole, Bindu Kanapuru
Seminars in Hematology. 2025-02-01 - Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes.Erica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, Bindu Kanapuru, Laleh Amiri-Kordestani
Value in Health. 2025-01-01 - 1 citationsFDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.Andrea C Baines, Bindu Kanapuru, Jay Zhao, Lauren S L Price, Nan Zheng
Clinical Cancer Research. 2024-12-16
Press Mentions
Suzetrigine’s Approval Signals a Shift in Non-Opioid Pain ManagementFebruary 4th, 2025- Cancer Drug’s Withdrawal a Good Thing? “Autopsy” Shows System Works, FDA SaysJanuary 27th, 2025
- Criteria for Selecting Who Can Enroll in Multiple Myeloma Clinical Trials May Exclude Patients from Minority GroupsApril 5th, 2023
- Join now to see all
